ArticlePloS one2025
Antithrombotic effect and plasma pharmacochemistry of Justicia Procumbens L.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Integrin β3: novel antiplatelet lignans 6'-Hydroxyjusticidin B and Neojusticin A from Justicia procumbens unveiled via multi-omics and biophysical validation.Natural products and bioprospecting · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceJusticia procumbens L. contains lignans with remarkable antiplatelet aggregation effects. Its ethyl acetate extract has demonstrated the efficacy of inhibiting platelet aggregation in preliminary tests. Identifying key components, elucidating the antithrombotic mechanism, and evaluating its potential for treating thrombotic diseases are of great significance.
methodsChemical analysis was conducted on the ethyl acetate extract of J. procumbens. Animal models of carotid artery and venous thrombosis, combined with proteomics analysis, were employed to study the antithrombotic mechanism.
resultsChemical analysis identified justicidin B (JB) and chinensinaphthol methyl ether (CME) as the major active antithrombotic constituents. The extract inhibited platelet aggregation by regulating relevant signaling pathways, showing potential in preventing both venous and arterial thrombosis.
conclusionsThis study confirmed that the ethyl acetate extract of J. procumbens, especially the lignan components JB and CME, can effectively inhibit platelet aggregation, showing promising prospects in treating thrombotic diseases. This provides ideas for the development of health products based on J. procumbens and lays a foundation for further clinical exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.